Sexually Transmitted Disease Surveillance, 2020 serves as a reminder that STDs remain a significant public health concern, even in the face of a pandemic. In 2020, COVID-19 significantly affected STD surveillance and prevention efforts. This report reflects the realities of a strained public health infrastructure, while simultaneously providing the most current data on reported cases of STDs in the United States. Trends presented in this report should be interpreted cautiously.
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more
